Actavis has launched a generic drug for prostate cancer, Bicalutamide, in the UK, France and Germany.
Bicalutamide, the generic version of AstraZeneca’s Casodex®, is used as a treatment for prostate cancer and will be available in tablet form in 50mg doses in all three markets, as well as in 150mg doses in the UK.
Bicalutamide Actavis was launched on day one, when the brand product’s patent expired; on 8 July in the UK and 9 July in Germany and France. Distribution of the product will commence immediately.
Commenting on the launch of Bicalutamide, Svend Andersen, Executive Vice President of Western Europe Sales, said: “We are pleased to be the first generic pharmaceutical company to bring this product to the market – creating value for patients at a lower price. Bicalutamide is an important product in Actavis’ portfolio. It is used in treating prostate cancer and also in combination with other treatments of malign diseases, prescribed by both hospitals and general practitioners.”
Actavis was able to launch generic Bicalutamide in some of its countries of operation as early as 2007, including the Czech Republic, Slovakia, Poland and Iceland.
Visit the Actavis website at www.actavis.com for more information on generic Bicalutamide for prostate cancer.
About Actavis Group
Actavis is one of the world’s leading generic pharmaceutical companies specialising in the development, manufacture and sale of generic pharmaceuticals. Based in Iceland, the company has operations in 40 countries, with 11,000 employees.
Enquiries
Actavis Group
Hjordis Arnadottir
Director, External Communications
Tel: (+354) 535 2300 / 840 7476
E-mail: harnadottir@actavis.com
Reykjavík, Iceland, 13.03.2025 - PiparTBWA has been named Advertising Agency of the Year for the…
London, UK – March 12, 2025 – Quirky Campers, the UK's leading platform for handcrafted…
Paris, March 11, 2025 – eXo Platform, a leading open-source provider of intranet and digital…
Tel Aviv, March 11, 2025 – Sasa Software, a global leader in advanced cybersecurity solutions…
Global Regression in Women's Rights Sparks UN Women National Committees’ 'March Forward' Campaign. Fri, Mar…
[Helsinki, Finland – March 7, 2025] – Savox Communications, a global leader in mission-critical communications…